Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06149910 · ClinicalTrials.gov registry record
Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma
A clinical trial of Multiple Myeloma and Multiple Myeloma Without Mention of Remission, sponsored by All4Cure.
- Recruiting
- Registry status
- 450
- Enrollment target
- 1
- Study location
NCT06149910 is a study of Multiple Myeloma and Multiple Myeloma Without Mention of Remission that is actively recruiting participants, run by All4Cure. The registered enrollment target is 450 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (18% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06149910, a study of Multiple Myeloma and Multiple Myeloma Without Mention of Remission, is actively recruiting participants, sponsored by All4Cure.
- RECRUITING
- Registry status
- 450 participants
- Enrollment target
- 1
- Study location
Study Summary
All4Cure is partnering with community oncology practices participating in the Quality Cancer Care Alliance (QCCA) and Exigent Research to develop a clinical pathway that standardizes the evaluation, treatment and ongoing management of patients with newly diagnosed multiple myeloma who wish to achieve and maintain MRD negativity. This is a longitudinal retrospective study that will collect data from three separate cohorts of patients with newly diagnosed multiple myeloma (NDMM). The cohorts classify patients based on whether care is delivered under an intention to adhere to an MRD-targeted clinical pathway, and if so, whether the implementation of that clinical pathway occurs through participation in the All4Cure platform vs. through written documentation. The three cohorts are labeled: Platform, Documentation, and Off-Pathway.
Conditions Studied
Interventions
- OTHER Multiple Myeloma Pathway
- OTHER All4Cure Platform
- OTHER Documentation Pathway
Study Locations (1)
Washington
- All4Cure - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2024-04-18 |
| Est. Completion | 2026-12-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06149910
The ClinicalTrials.gov registry entry for NCT06149910 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (18% lower). The listed sponsor is All4Cure, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Multiple Myeloma Pathway is the first listed.
NCT06149910 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT06149910 about?
NCT06149910 is a clinical study titled "Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma". All4Cure is partnering with community oncology practices participating in the Quality Cancer Care Alliance (QCCA) and Exigent Research to develop a clinical pathway that standardizes the evaluation, treatment and ongoing management of patients with newly diagnosed multiple myeloma who wish to achiev...
What is the current status of trial NCT06149910?
This trial is currently recruiting. The enrollment target is 450 participants. The study started on 2024-04-18. Estimated completion is 2026-12-01.
What conditions does trial NCT06149910 study?
This clinical trial studies the following conditions: Multiple Myeloma, Multiple Myeloma Without Mention of Remission.
What interventions are being tested in trial NCT06149910?
The interventions under investigation include: Multiple Myeloma Pathway (OTHER), All4Cure Platform (OTHER), Documentation Pathway (OTHER).
Who is sponsoring clinical trial NCT06149910?
This trial is sponsored by All4Cure, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06149910 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
RECRUITING
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Explore more on PlainTrial
Multiple Myeloma
All registered trials for this condition
Multiple Myeloma Without Mention of Remission
All registered trials for this condition
Washington
All trials with a study site in Washington
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.